2024-09-28T12:20:34-05:00 2023-12-31 953001179 WINDES INC 2050 MAIN ST STE 1300 IRVINE CA 92614 990 2023-01-01 953772528 PEDIATRIC CANCER RESEARCH FOUNDATION PEDI 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 THOMAS BRENNAN TREASURER 9498596312 2024-09-24 1 1 ELEANOR A LIVINGSTON CPA MST P00226461 9498529433 2024-09-24 2023 2024-10-15 13:58:12Z DANIELLE FRAGALLA 2151 MICHELSON DRIVE 180 IRVINE CA 92612 7030816 0 X WWW.PCRF-KIDS.ORG X 1982 CA THE FOUNDATION'S MISSION IS TO IMPROVE THE CARE, QUALITY OF LIFE AND SURVIVAL RATE OF CHILDREN WITH MALIGNANT DISEASES. THE FOUNDATION RAISES FUNDS TO SUPPORT STATE-OF-THE-ART RESEARCH THAT WILL ULTIMATELY LEAD TO A CURE FOR ALL CHILDHOOD CANCERS. 20 20 9 500 0 0 3808467 4074348 371375 0 10776 49338 -1072633 -139194 3117985 3984492 2568802 2040951 0 0 552779 777650 0 0 935852 1066087 908569 4187668 3727170 -1069683 257322 3281205 3305936 1816853 1575973 1464352 1729963 FUND RESEARCH TO POWER CURES THAT REDUCE THE PERCENTAGE OF CHILDREN WHO PERISH FROM CANCER UNTIL THAT NUMBER REACHES ZERO. 0 0 2638079 2040951 PEDIATRIC CANCER RESEARCH ACTIVITIES - PRIMARY FUNDING SOURCE FOR RESEARCH STUDIES, STAFF & EQUIPMENT NEEDS FOR PEDIATRIC CANCER RESEARCH LABS. SEE SCHEDULE I FOR ADDITIONAL DETAIL. 2638079 1 1 0 0 0 0 0 0 0 0 1 0 1 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 5 0 1 9 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 20 20 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY NJ X X X DANIELLE FRAGALLA 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 STEVE GIUSTO PRESIDENT 1.00 X X 0 0 0 JOHN WEINER VICE-PRESIDENT 1.00 X X 0 0 0 TOM BRENNAN TREASURER 1.00 X X 0 0 0 KEITH KOELLER SECRETARY 1.00 X X 0 0 0 BETH ABRAMS DIRECTOR 1.00 X 0 0 0 SUSIE BUCHAN DIRECTOR 1.00 X 0 0 0 JOHN COON DIRECTOR 1.00 X 0 0 0 TIM CROMWELL DIRECTOR 1.00 X 0 0 0 CHERIE DALY DIRECTOR 1.00 X 0 0 0 SCOTT ECKER DIRECTOR 1.00 X 0 0 0 ELIZABETH MCNULTY DIRECTOR 1.00 X 0 0 0 JANET MITCHELL DIRECTOR 1.00 X 0 0 0 CAMERON MUNSON DIRECTOR 1.00 X 0 0 0 AMANDA SARATSIS DIRECTOR 1.00 X 0 0 0 LEN SHULMAN DIRECTOR 1.00 X 0 0 0 JOHN VALLELY DIRECTOR 1.00 X 0 0 0 TROY VARENCHIK DIRECTOR 1.00 X 0 0 0 DARTH VAUGHN DIRECTOR 1.00 X 0 0 0 NICOLE WILKINS DIRECTOR 1.00 X 0 0 0 JASON O'DONNELL DIRECTOR 1.00 X 0 0 0 JERI WILSON EXECUTIVE DIRECTOR 40.00 X 221538 0 19350 221538 0 19350 1 0 1 0 RED FOX COMMUNICATIONS 67 FOREST ROAD TENAFLY NJ 07670 MARKETING SERVICES 180000 1 1764148 161825 2148375 177326 4074348 25508 25508 1525762 1501932 23830 23830 23830 1405198 1764148 1544392 -139194 -139194 3984492 0 0 -89856 1953951 1953951 87000 87000 240888 75170 25338 140380 474256 147994 49885 276377 13536 4224 1424 7888 48970 15281 5151 28538 9121 871 300 7950 74270 24252 8351 41667 288333 96164 33098 159071 208498 54044 154454 14170 4627 1593 7950 139082 43415 14612 81055 12239 2159 2503 7577 OTHER PROGRAM SERVICES 119237 119237 POSTAGE, PRINTING, AND 19293 3859 5787 9647 MISCELLANEOUS 18033 5831 4371 7831 CREDIT CARD FEES 6293 826 5467 3727170 2638079 153239 935852 1126434 933546 222357 594253 153450 0 0 121345 181147 113268 48941 48941 0 0 987450 999710 250000 250000 360367 293814 3281205 3305936 183556 247474 1068726 846422 186355 164181 378216 317896 1816853 1575973 X 1464352 1729963 1464352 1729963 3281205 3305936 257322 8289 0 X 0 1 X 1 0 X 2746067 3436116 3381857 3808467 4071163 17443670 2746067 3436116 3381857 3808467 4071163 17443670 277926 17165744 18443 8518 66 10776 25508 63311 202669 48753 52706 47304 351432 17858413 371375 0.96120 0.94980 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3156 3156 0 45785 45785 0 0 INVESTMENT IN ONCOHEROES BIOSCIENCES, INC. 250000 C 250000 DEPOSITS 7570 OPERATING LEASE RIGHT-OF-USE ASSET 286244 293814 OPERATING LEASE LIABILITY 317896 317896 X 4000296 8289 7515 15804 3984492 0 3984492 3734685 7515 7515 3727170 0 3727170 PART X, LINE 2: FIN 48: FASB ASC TOPIC 740, INCOME TAXES, REQUIRES MANAGEMENT TO EVALUATE THE TAX POSITIONS TAKEN BY THE FOUNDATION AND TO RECOGNIZE A TAX LIABILITY IF THE FOUNDATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE INTERNAL REVENUE SERVICE. MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE FOUNDATION AND HAS CONCLUDED THAT, AS OF DECEMBER 31, 2023, THERE ARE NO UNCERTAIN POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE FOUNDATION IS SUBJECT TO ROUTINE AUDITS BY THE TAXING JURISDICTIONS. THE STATUTE OF LIMITATIONS FOR FEDERAL AND CALIFORNIA PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. 2023 REACHING FOR THE CURE 682292 572977 109315 20862 2492 347627 CULINARY EXPERIENCE 456102 66307 389795 18130 45773 31445 186227 14 2030952 1124864 906088 233676 173704 4085 480371 3169346 1764148 1405198 272668 221969 35530 1014225 1544392 -139194 1 NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595 131099420 501(C)(3) 550000 0 PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE UNIVERSITY OF FLORIDA 207 GRINTER HALL GAINESVILLE FL 32611 596002052 501(C)(3) 50000 0 INVESTIGATING THE IMMUNE RESPONSE TO RNA-LIPID NANOPARTICLE VACCINES IN A CLINICAL TRIAL FOR CANINES WITH OSTEOSARCOMA MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501(C)(3) 50000 0 TARGETING TRANSCRIPTIONAL DEPENDENCIES IN ATYPICAL TERATOID RHABDOID TUMOR NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE GBH-SC1-47 NEW YORK NY 10016 135562308 501(C)(3) 50000 0 MODULATING THE IMMUNE MICROENVIRONMENT IN PEDIATRIC ACUTE MYELOID LEUKEMIA MD ANDERSON 1515 HOLCOMBE BLVD HOUSTON TX 77030 766001118 501(C)(3) 91717 0 COMBINING A NOVEL DENDRITIC CELL VACCINE WITH CHECKPOINT BLOCKADE FOR OSTEOSARCOMA THERAPY DANA FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 105000 0 PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA CASE WESTERN 10900 EUCLID AVENUE CLEVENLAND OH 44106 341018992 501(C)(3) 75000 0 USE OF MR FINGERPRINTING FOR DETERMINING RESPONSE TO IMMUNOTHERAPY IN PEDIATRIC BRAIN TUMORS BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA BCM 310 HOUSTON TX 77030 741613878 501(C)(3) 75000 0 OFF-THE-SHELF COMBINATION CANCER IMMUNOTHERAPY WITH ONCOLYTIC ADENO-IMMUNOTHERAPY AND CAR NK CELL THERAPY FOR PEDIATRIC SARCOMA MEMORIAL SLOAN KETTERING 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 150000 0 TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS UNIVERSITY OF ALABAMA BIRMINGHAM 1600 7TH AVENUE SOUTH LOWDER 512 BIRMINGHAM AL 35233 636005396 501(C)(3) 74007 0 INTRANASAL DELIVERY OF TARGETING NANOLIPOSOMAL THERAPEUTICS FOR PEDIATRIC GLIOMA HOPE FOR HENRY 2440 WISCONSIN AVE NW SUITE 201 WASHINGTON DC 20007 200244173 501(C)(3) 50000 0 REWARDING PEDIATRIC PATIENTS AND ELEVATING THEIR CARE UCLA FOUNDATION 10889 WILSHIRE BLVD SUITE 150 LOS ANGELES CA 90027 952250801 501(C)(3) 70000 0 RESEARCH INTO MULTIDISCIPLINARY APPROACH TO SIGNIFICANTLY AND POSITIVELY IMPROVE THE QUALITY OF LIFE OF AND QUALITY OF CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER. CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 25000 0 REPORTER T CELL LINE GENERATION UCSF 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94118 946036493 501(C)(3) 115000 0 TACL2020-004: A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA STANFORD UNIVERSITY 3172 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 115000 0 TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML 18 0 SCHOLARSHIPS 96 87000 PART I, LINE 2: ACCORDING TO ITS ESTABLISHED GUIDELINES, PCRF SUPPORTS RESEARCH INTENDED TO DEVELOP INNOVATIVE APPROACHES TO THE TREATMENT, DIAGNOSIS AND PREVENTION OF PEDIATRIC CANCER. GRANTS ARE AWARDED TO PRINCIPAL INVESTIGATORS HOLDING AN MD OR PHD DEGREE WORKING IN DOMESTIC RESEARCH INSTITUTIONS. GRANTS ARE SUBJECT TO SCIENTIFIC PEER REVIEW BY AN INDEPENDENT COMMITTEE OF ONCOLOGISTS OR SCIENTISTS AND ARE ALSO SUBJECT TO BUDGETARY CONSTRAINTS AS DETERMINED BY PCRF'S BOARD OF DIRECTORS. REVIEW CRITERIA INCLUDES: 1) THE PROBABILITY OF AN ADVANCE IN PREVENTION, DIAGNOSIS OR TREATMENT FOR THE NEAR-TERM, 2) NOVELTY OF THE CONCEPT AND STRATEGY, 3) CLARITY OF PRESENTATION, 4) EXPERIENCE AND QUALIFICATIONS OF THE INVESTIGATORS, 5) ADEQUACY OF RESOURCES AND ENVIRONMENT, AND, 6) OVERALL PLAN FOR BRINGING THE RESEARCH FINDINGS TO CLINICAL APPLICATION. FUNDING REQUESTS MUST BE CONSISTENT WITH THE OBJECTIVES OF THE PROJECT AND GENERALLY NOT INCLUDE OVERHEAD OR INDIRECT COSTS. CERTAIN GRANT PAYMENTS ARE MADE ONLY AFTER SUBMISSION AND REVIEW OF QUARTERLY REPORTS. SUBMISSION OF SCIENTIFIC RESULTS AND UPDATES MUST BE MADE ANNUALLY. X X X 0 0 0 0 0 0 0 0 0 JERI WILSON EXECUTIVE DIRECTOR 211538 0 10000 0 0 0 12900 0 6450 0 240888 0 0 0 X 11 26528 FAIR MARKET VALUE X 1 12000 FAIR MARKET VALUE X DONATED AUCTION ITEMS 80 138798 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION B, LINE 11B DESCRIBE THE PROCESS THE ORGANIZATION USES TO REVIEW FORM 990. THE FINAL VERSION OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE AFTER THE DETAILED REVIEW IS COMPLETED BY THE FINANCIAL DIRECTOR AND THE TREASURER. THE TREASURER DISTRIBUTES A COPY OF THE FINAL VERSION OF THE FORM 990 TO THE BOARD OF DIRECTORS FOR FINAL REVIEW PRIOR TO FILING. THE RETURN IS FILED AFTER THE BOARD REVIEWS THE FORM 990. FORM 990, PART VI, SECTION B, LINE 12C DESCRIBE HOW THE ORGANIZATION MONITORS AND ENFORCES COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY. ALL BOARD MEMBERS, KEY EMPLOYEES, AND MANAGEMENT ARE COVERED BY THE CONFLICT OF INTEREST POLICY. DETERMINATIONS OF CONFLICT AND REVIEW OF CONFLICT IS PERFORMED AT THESE VARIOUS LEVELS OF THE ORGANIZATION. APPROPRIATE ACTION DEPENDING ON THE CONFLICT IS TAKEN BY MANAGEMENT, KEY EMPLOYEES AND THE BOARD. DISCLOSURE FORMS ARE REQUIRED ANNUALLY BY EACH MEMBER OF THE BOARD OF DIRECTORS, KEY EMPLOYEES, AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 DESCRIBE THE PROCESS FOR DETERMINING COMPENSATION OF THE ORGANIZATIONS MANAGEMENT AND KEY EMPLOYEES. THE COMPENSATION COMMITTEE AND BOARD APPROVES COMPENSATION OF TOP MANAGEMENT. THE COMPENSATION COMMITTEE REVIEWED INDUSTRY STANDARD COMPENSATIONS. FORM 990, PART VI, SECTION C, LINE 19 DESCRIBE HOW THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. THE FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. PEDIATRIC CANCER RESEARCH FOUNDATION NEW YORK A NOT FOR PROFIT CORPORATION 2151 MICHELSON DRIVE IRVINE CA 92618 273051697 FUNDING SOURCE FOR RESEARCH NY 501(C)(3) LINE 4 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0